BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation…
152,900€
-0,65%
Echtzeit-Aktienkurs AstraZeneca PLC
Bid:
Ask:
Nachrichten zur AstraZeneca PLC Aktie
AstraZeneca CEO Soriot on Pharmaceuticals in China
AstraZeneca CEO Pascal Soriot discusses the drugmaker’s business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships…
Astra, Pfizer Boost China Bets Despite US Drive to Decouple
The chief executive officers of AstraZeneca Plc and Pfizer Inc. pledged to support expansion of China’s biopharmaceutical industry, even as…
AstraZenecas (AZN) Ultomiris Gets FDA Nod for New Indication
FDA approves AstraZenecas (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved…
UBS stuft ASTRAZENECA auf Sell
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9900…
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower…
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of…
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value…
What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals
…
Fusion Pharmaceuticals Stock Soars. It’s Being Acquired by AstraZeneca in $2.4 Billion Deal.
…
Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
The company is working on radiopharmaceuticals treatments for cancer.…
AstraZeneca: Der Pharma-Riese bleibt in Sachen M&A sehr aktiv - Aktienanalyse
Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting
AstraZeneca PLC (LSE:AZN) is acquiring Canadas Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively keep up with Joneses…
AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
The deal is AstraZenecas second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to…
Pharmakonzern Astrazeneca will Onkologie-Spezialisten Fusion übernehmen
CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca will den kanadischen Krebsspezialisten Fusion Pharmaceuticals übernehmen. Dabei…
AstraZeneca will buy Fusion Pharmaceuticals for ~$2B
…
AstraZeneca to Buy Fusion Pharma for Up to $2.4 Billion
AstraZeneca Plc agreed to buy Fusion Pharmaceuticals Inc. for as much as $2.4 billion as it seeks to transform cancer…
AstraZeneca to buy Fusion Pharma for $2 billion in cash By Reuters
AstraZeneca to buy Fusion Pharma for $2 billion in cash…
AstraZeneca to acquire Fusion
19 March 2024
AstraZeneca to acquire Fusion to accelerate the development of
next-generation radioconjugates to treat cancer
Includes actinium-based clinical-stage radioconjugate targeting PSMA…
AstraZeneca caps inhaler costs at $35 for eligible US patients By Investing.com
AstraZeneca caps inhaler costs at $35 for eligible US patients…
AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month By Reuters
AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month…
Kommunen fordern "Atempause" bei Flüchtlingen - TE-Wecker am 18. März 2024
Kommunen fordern "Atempause" bei Flüchtlingen ++ EU schließt 7,4-Milliarden-Flüchtingsdeal mit Ägypten ++ Teilurteil in Corona-Prozess gegen AstraZeneca erwartet ++ neue…
Pharma Stock Roundup: AZNs New Acquisition, FDA Updates for NVO & LLY and More
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lillys (LLY) donanemab and approves…
AstraZeneca: Milliardenschwerer Deal verkündet - Aktienanalyse
Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…
Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come
A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca…
AstraZeneca: Rating gesenkt
Frankfurt (www.aktiencheck.de) - Rating-Update:
Die Analysten von ODDO BHF stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG,…
ANALYSE-FLASH: Berenberg senkt Ziel für Astrazeneca auf 12000 Pence - 'Buy'
HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Astrazeneca von 12500 auf…
ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence
NEW YORK (dpa-AFX Broker) - Die US-Bank JPMorgan hat Astrazeneca auf "Overweight" mit einem Kursziel…
ANALYSE-FLASH: Deutsche Bank senkt Astrazeneca auf 'Sell' auf Ziel 9500 Pence
FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research hat Astrazeneca nach Zahlen von "Hold" auf "Sell"…
Lukratives Krebsgeschäft beschert Astrazeneca Gewinnsprung
CAMBRIDGE (dpa-AFX) - Ein gutes Geschäft mit Krebsmedikamenten gleicht bei Astrazeneca den Umsatzschwund mit Covid-Produkten…